Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8467150 | 0.83 | CYP3A4 (0.39) | CYP3A4TDP1ESR1ESR2 | |
| SCHEMBL10024962 | 0.82 | CYP3A4 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL23581097 | 0.82 | CYP3A4 (0.46) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL7165274 | 0.78 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL7089620 | 0.78 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL16292891 | 0.78 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL29053288 | 0.78 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL668759 | 0.78 | CYP3A4 (0.42) | CYP3A4TDP1DRD1ESR1ESR2 | |
| SCHEMBL14954728 | 0.77 | CYP3A4 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 | |
| Hydrochloric Acid SCHEMBL31338861 | 0.77 | DRD1 (0.41) | CYP3A4TDP1DRD1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1414783-B1 | METHOD FOR THE PRODUCTION OF AMINES BY REDUCTIVE AMINATION OF CARBONYL COMPOUNDS UNDER TRANSFER-HYDROGENATION CONDITIONS | EVONIK DEGUSSA GMBH (DE) | 2009-07-15 | — | — | EP | disclosed |
| US-7230134-B2 | Method for the production of amines by reductive amination of carbonyl compounds under transfer-hydrogenation conditions | DEGUSSA AG (DE) | 2007-06-12 | — | — | US | disclosed |
| US-20040267051-A1 | Method for the production of amines by reductive amination of carbonyl compounds under transfer-hydrogenation conditions | EVONIK DEGUSSA GMBH (DE) | 2004-12-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040267051-A1 | Method for the production of amines by reductive amination of carbonyl compounds under transfer-hydrogenation conditions | HNMT, AADAT, ADH5 | CYP3A4 485/4885TDP1 4457/4885DRD1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.